Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

Completed · Phase 3 · Has a placebo group

Conditions studied: Hot Flashes

In brief

Depomed's Gabapentin Extended Release (G-ER) is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.

Key facts

Study ID

NCT00755417

Run by

Depomed

People needed

541

Starts

2008-09-01

Expected to finish

2009-10-01

Last updated by the study team

2012-03-07

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal women aged 18 to 70 years experiencing ≥7 moderate to severe hot flashes per day (or ≥50 per week) accompanied by sweating during previous 30 days or longer.
• Had amenorrhea for ≥12 months, amenorrhea for 6 to 12 months with serum follicle-stimulating hormone (FSH) levels >40 mIU/mL, or was ≥6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
• Willing to discontinue the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; intrauterine progestin; progestin implants; injectable estrogen; topical progesterone cream.
• Had to have daily average of ≥7 moderate to severe hot flashes and had to complete ≥4 days of diary entries during baseline week to be randomized.
• If treated with antidepressants, could not have had any changes in drug doses during past month.
• Other Inclusions apply.

You may not qualify if…

• Patient treated with a gonadotrophin releasing hormone agonist, anti-estrogens, or aromatase inhibitors within 2 months prior to study entry.
• Patient treated with estrogen pellets or progestin injectable drugs within 6 months prior to study entry.
• Patient experience only nighttime hot flashes or worked night shifts on a regular basis.
• Patient was concurrently treated with gabapentin for other indications. If patient was using gabapentin for treatment of hot flashes, she could be screened after a 7-day washout period provided hot flashes returned.
• Patient had previously experienced dose-limiting adverse events that prevented titration of gabapentin to an effective dose.
• Patient had a hypersensitivity to gabapentin.
• Patient was in an immunocompromised state.
• Patient had a malignancy other than basal cell carcinoma within 2 years prior to study entry.
• Patient had gastric reduction surgery, severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome, uncontrolled inflammatory bowel disease, or unexplained weight loss.
• Patient had clinically significant abnormal chemistry or hematology results, or calculated glomerular filtration rate <60 mL/min.
• Patient had history of substance abuse within year prior to study entry.
• Patient was concurrently taking morphine.
• Patient had history of chronic hepatitis B or C, hepatitis within 3 months prior to study entry, or history of human immunodeficiency virus.
• Other Exclusions apply.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Montgomery, Alabama, United States
• Study site — Tempe, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Berkely, California, United States
• Study site — La Mesa, California, United States
• Study site — San Diego, California, United States
• Study site — Santa Rosa, California, United States
• Study site — Denver, Colorado, United States
• Study site — Lakewood, Colorado, United States
• Study site — Waterbury, Connecticut, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Clearwater, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — New Port Richey, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — St. Petersburg, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Sandy Springs, Georgia, United States
• Study site — Savannah, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Madisonville, Kentucky, United States
• Study site — Fall River, Massachusetts, United States
• Study site — Edina, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.